(A) Staining of RbKD OKM iPSCs for Oct4, Sox2, Nanog, and AP activity. Scale bars, 100 mm, or 200 mm for AP.
(B) Oct4 and Nanog were targeted for gene activation using the CRISPR-on technique (see ). RT-qPCR was performed 5 days after Cas9-VP64 activation and is shown relative to an rtTA-only control.
(C) Pituitaries from representative Rblox/lox; Rosa26CreER mice for all Sox2 alleles (+, wild-type; lx, lox/lox) 9 weeks after tamoxifen injection.
(D) Box and whisker plots of the pituitary size from mice of the genotypes in , including Rblox/lox; Rosa+/+ mice as controls.
(E) Pituitary sections of Rblox/lox; Rosa26CreER mice that are either Sox2+/+ or Sox2lox/lox 9 weeks after tamoxifen injection, stained with H&E (top) or Ki67 (bottom). The Pars Nervosa (PN), Pars intermedia (PI), Pars distalis (PD), and residual cleft (rc) are shown. The green channel was exposed equally between the two images. Representative images are shown.
(F) Quantification of Ki67 in Rblox/lox; Rosa26CreER pituitaries with the shown Sox2 genotypes (+, wild-type; lx, lox/lox) 9 weeks after tamoxifen injection. Percentages were calculated from four pituitaries, except the CreER− control, which had n = 3. Dashed line indicates the number of positive cells counted in the secondary-only control.
All plots, unless noted, display the mean ± SD where *p < 0.05, **p < 0.01, and ns = not specified. See also .